EP1667730A4 - Zusammensetzungen und verfahren zur behandlung von entzündlicher lungenerkrankung - Google Patents

Zusammensetzungen und verfahren zur behandlung von entzündlicher lungenerkrankung

Info

Publication number
EP1667730A4
EP1667730A4 EP04781986A EP04781986A EP1667730A4 EP 1667730 A4 EP1667730 A4 EP 1667730A4 EP 04781986 A EP04781986 A EP 04781986A EP 04781986 A EP04781986 A EP 04781986A EP 1667730 A4 EP1667730 A4 EP 1667730A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
lung disease
treating inflammatory
inflammatory lung
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP04781986A
Other languages
English (en)
French (fr)
Other versions
EP1667730B1 (de
EP1667730A2 (de
Inventor
Eckhard R Podack
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Miami
Original Assignee
University of Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Miami filed Critical University of Miami
Priority to EP10188265.2A priority Critical patent/EP2353615B1/de
Publication of EP1667730A2 publication Critical patent/EP1667730A2/de
Publication of EP1667730A4 publication Critical patent/EP1667730A4/de
Application granted granted Critical
Publication of EP1667730B1 publication Critical patent/EP1667730B1/de
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
EP04781986.7A 2003-08-20 2004-08-20 Zusammensetzungen und verfahren zur behandlung von entzündlicher lungenerkrankung Not-in-force EP1667730B1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP10188265.2A EP2353615B1 (de) 2003-08-20 2004-08-20 Zusammensetzungen und Verfahren zur Behandlung von entzündlicher Lungenerkrankung

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US49655503P 2003-08-20 2003-08-20
US49662503P 2003-08-20 2003-08-20
US49976803P 2003-09-03 2003-09-03
US54522604P 2004-02-17 2004-02-17
PCT/US2004/027407 WO2005018571A2 (en) 2003-08-20 2004-08-20 Compositions and methods for treating inflammatory lung disease

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP10188265.2A Division EP2353615B1 (de) 2003-08-20 2004-08-20 Zusammensetzungen und Verfahren zur Behandlung von entzündlicher Lungenerkrankung
EP10188265.2 Division-Into 2010-10-20

Publications (3)

Publication Number Publication Date
EP1667730A2 EP1667730A2 (de) 2006-06-14
EP1667730A4 true EP1667730A4 (de) 2008-06-25
EP1667730B1 EP1667730B1 (de) 2013-06-26

Family

ID=34222584

Family Applications (2)

Application Number Title Priority Date Filing Date
EP04781986.7A Not-in-force EP1667730B1 (de) 2003-08-20 2004-08-20 Zusammensetzungen und verfahren zur behandlung von entzündlicher lungenerkrankung
EP10188265.2A Not-in-force EP2353615B1 (de) 2003-08-20 2004-08-20 Zusammensetzungen und Verfahren zur Behandlung von entzündlicher Lungenerkrankung

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP10188265.2A Not-in-force EP2353615B1 (de) 2003-08-20 2004-08-20 Zusammensetzungen und Verfahren zur Behandlung von entzündlicher Lungenerkrankung

Country Status (6)

Country Link
US (2) US20080233119A2 (de)
EP (2) EP1667730B1 (de)
CA (1) CA2536086C (de)
DK (1) DK1667730T3 (de)
ES (1) ES2428321T3 (de)
WO (1) WO2005018571A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090317388A1 (en) * 2005-05-25 2009-12-24 Linda Burkly Tl1a in treatment of disease
CA2621083C (en) 2005-08-30 2017-04-11 University Of Miami Immunomodulating tumor necrosis factor receptor 25 (tnfr25) agonists, antagonists and immunotoxins
US9896511B2 (en) 2007-01-10 2018-02-20 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease comprising administering such antibodies
JP5745854B2 (ja) * 2007-11-13 2015-07-08 テバ バイオファーマシューティカルズ ユーエスエー インコーポレーティッド Ｔｌ１ａに対するヒト化抗体
US20110195048A1 (en) * 2008-10-08 2011-08-11 Podack Eckhard R Regulation of lymphocytes and uses therefor
WO2010062960A2 (en) 2008-11-26 2010-06-03 Cedars-Sinai Medical Center METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE
KR20120089259A (ko) * 2009-08-03 2012-08-09 유니버시티 오브 마이애미 Ｔ 조절 세포의 생체 내 확장 방법
WO2011106707A2 (en) * 2010-02-26 2011-09-01 Human Genome Sciences, Inc. Antibodies that specifically bind to dr3
JO3375B1 (ar) * 2010-11-08 2019-03-13 Regeneron Pharma أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a)
CA2836898A1 (en) 2011-05-20 2012-11-29 Government Of The United States, As Represented By The Secretary, Department Of Health And Human Services Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology and antibodies thereof
WO2013044298A1 (en) 2011-09-30 2013-04-04 Cephalon Australia Pty Ltd Antibodies against tl1a and uses thereof
KR102565827B1 (ko) 2013-01-09 2023-08-11 유니버시티 오브 마이애미 TL1A-Ig 융합 단백질을 사용한 T 조절 세포의 조절을 위한 조성물 및 방법
CN105246501B (zh) 2013-03-27 2021-01-12 雪松-西奈医学中心 通过抑制tl1a的功能和相关信号传导途径来减轻并逆转纤维化和炎症
EP3022295A4 (de) 2013-07-19 2017-03-01 Cedars-Sinai Medical Center Signatur des tl1a (tnfsf15)-signalweges
EP3041580A4 (de) * 2013-09-06 2017-05-03 Cedars-Sinai Medical Center Systeme, vorrichtungen und verfahren für anti-tl1a-therapie
WO2015166486A1 (en) * 2014-04-28 2015-11-05 The National Institute for Biotechnology in the Negev Ltd. Variants of dr3 and use thereof
US9982057B2 (en) 2014-11-17 2018-05-29 Pelican Therapeutics, Inc. Human TNFRSF25 antibody
US20180156781A1 (en) * 2015-05-15 2018-06-07 Cedars-Sinai Medical Center Models, methods and compositions for treating inflammatory bowel disease
TWI703158B (zh) 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
WO2017077715A1 (en) * 2015-11-02 2017-05-11 La Jolla Institute For Allergy & Immunology Method and medicament for treating airway and/or lung diseases
CR20180365A (es) 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
EP3430172A4 (de) 2016-03-17 2019-08-21 Cedars-Sinai Medical Center Verfahren zur diagnose einer entzündlichen darmerkrankung durch rnaset2
WO2017214547A1 (en) 2016-06-09 2017-12-14 Pelican Therapeutics, Inc. Anti-tnfrsf25 antibodies
WO2022177963A1 (en) 2021-02-17 2022-08-25 Prometheus Biosciences, Inc. Anti-cd30l antibodies and uses thereof
CN116223818B (zh) * 2023-05-09 2023-07-21 四川大学华西医院 Dr3蛋白检测试剂在制备筛查aecopd的试剂盒的用途及筛查aecopd的试剂盒

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000064465A1 (en) * 1999-04-22 2000-11-02 Human Genome Sciences, Inc. Death domain containing receptors
WO2001035995A2 (en) * 1999-11-19 2001-05-25 Tittle Thomas V Tr3-specific binding agents and methods for their use
WO2003000286A1 (fr) * 2001-06-22 2003-01-03 Daiichi Suntory Pharma Co., Ltd. Remedes pour maladies eosinophiliques
WO2003043583A2 (en) * 2001-11-20 2003-05-30 Seattle Genetics, Inc. Treatment of immunological disorders using anti-cd30 antibodies

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
US5264563A (en) 1990-08-24 1993-11-23 Ixsys Inc. Process for synthesizing oligonucleotides with random codons
US5462990A (en) * 1990-10-15 1995-10-31 Board Of Regents, The University Of Texas System Multifunctional organic polymers
US7597886B2 (en) * 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US20030129189A1 (en) * 1994-11-07 2003-07-10 Guo-Liang Yu Tumor necrosis factor-gamma
WO1997033904A1 (en) * 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Death domain containing receptors
US7357927B2 (en) * 1996-03-12 2008-04-15 Human Genome Sciences, Inc. Death domain containing receptors
BR9908267A (pt) * 1998-02-27 2000-10-24 Univ Pennsylvania Plasmìdeo, composição farmacêutica, processos para induzir uma resposta imunológica em um indivìduo contra um imunógeno, para imunizar um indivìduo contra uma infecção por vìrus de herpes simples e para tratar um indivìduo que tem uma doença autoimune, vacina recombinante, e, patógeno atenuado vivo
EA004590B1 (ru) * 1999-01-15 2004-06-24 Байоджен, Инк. Способ блокировки развития, или снижения тяжести, или проявлений заболевания "трасплантат против хозяина"
IL145676A0 (en) * 1999-04-12 2002-06-30 Genentech Inc Tumor necrosis factor homologs and nucleic acids encoding the same
US6652854B2 (en) * 2000-08-08 2003-11-25 Immunex Corporation Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L
AU1092602A (en) * 2000-10-24 2002-05-06 New Ind Res Organization Genomes participating in rheumatoid arthritis, method of the diagnosis thereof, method of evaluating the onset possibility thereof, diagnostic kit for detectingthem and therapeutic method and remedies for rheumatoid arthritis
US20090317388A1 (en) * 2005-05-25 2009-12-24 Linda Burkly Tl1a in treatment of disease
CA2836898A1 (en) * 2011-05-20 2012-11-29 Government Of The United States, As Represented By The Secretary, Department Of Health And Human Services Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology and antibodies thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000064465A1 (en) * 1999-04-22 2000-11-02 Human Genome Sciences, Inc. Death domain containing receptors
WO2001035995A2 (en) * 1999-11-19 2001-05-25 Tittle Thomas V Tr3-specific binding agents and methods for their use
WO2003000286A1 (fr) * 2001-06-22 2003-01-03 Daiichi Suntory Pharma Co., Ltd. Remedes pour maladies eosinophiliques
EP1405645A1 (de) * 2001-06-22 2004-04-07 Daiichi Suntory Biomedical Research Limited Mittel zur behandlung von eosinophilen-erkrankungen
WO2003043583A2 (en) * 2001-11-20 2003-05-30 Seattle Genetics, Inc. Treatment of immunological disorders using anti-cd30 antibodies

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
AKBARI OMID ET AL: "Essential role of NKT cells producing IL-4 and IL-13 in the development of allergen-induced airway hyperreactivity.", NATURE MEDICINE, vol. 9, no. 5, May 2003 (2003-05-01), pages 582 - 588, XP002453200, ISSN: 1078-8956 *
GRUENIG G ET AL: "REQUIREMENT FOR IL-13 INDEPENDENTLY OF IL-4 IN EXPERIMENTAL ASTHMA", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 282, 18 December 1998 (1998-12-18), pages 2261 - 2263, XP002948380, ISSN: 0036-8075 *
LI L ET AL: "Effects of Th2 cytokines on chemokine expression in the lung: IL-13 potently induces eotaxin expression by airway epithelial cells.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 1 MAR 1999, vol. 162, no. 5, 1 March 1999 (1999-03-01), pages 2477 - 2487, XP002460824, ISSN: 0022-1767 *
MATTES J ET AL: "IL-13 induces airways hyperreactivity independently of the IL-4R alpha chain in the allergic lung.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 1 AUG 2001, vol. 167, no. 3, 1 August 2001 (2001-08-01), pages 1683 - 1692, XP002453199, ISSN: 0022-1767 *
MIGONE THI-SAU ET AL: "TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator", IMMUNITY, CELL PRESS, US, vol. 16, no. 3, March 2002 (2002-03-01), pages 479 - 492, XP002397922, ISSN: 1074-7613 *
NAM SANG-YUN ET AL: "CD30 deficiency diminishes airway eosinophilia in a mouse model of pulmonary inflammation.", FASEB JOURNAL, vol. 17, no. 7, 14 April 2003 (2003-04-14), & 90TH ANNIVERSARY ANNUAL MEETING OF THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS; DENVER, CO, USA; MAY 06-10, 2003, pages C14, XP009093136, ISSN: 0892-6638 *
PURELLO-D'AMBROSIO F ET AL: "Effect of fluticasone propionate on soluble CD30 release in patients with severe allergic asthma", JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY, vol. 10, no. 5, September 2000 (2000-09-01), pages 283 - 285, XP009093129, ISSN: 1018-9068 *
WANG EDDIE C Y ET AL: "DR3 regulates negative selection during thymocyte development", MOLECULAR AND CELLULAR BIOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, US, vol. 21, no. 10, May 2001 (2001-05-01), pages 3451 - 3461, XP002208363, ISSN: 0270-7306 *
WILLS-KARP M ET AL: "INTERLEUKIN-13: CENTRAL MEDIATOR OF ALLERGIC ASTHMA", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 282, 18 December 1998 (1998-12-18), pages 2258 - 2260, XP002948381, ISSN: 0036-8075 *

Also Published As

Publication number Publication date
CA2536086C (en) 2013-03-19
ES2428321T3 (es) 2013-11-07
DK1667730T3 (da) 2013-09-23
EP2353615A2 (de) 2011-08-10
WO2005018571A2 (en) 2005-03-03
CA2536086A1 (en) 2005-03-03
EP2353615A3 (de) 2011-11-09
WO2005018571A3 (en) 2005-06-16
EP1667730B1 (de) 2013-06-26
US20120328559A1 (en) 2012-12-27
EP1667730A2 (de) 2006-06-14
US20080003221A1 (en) 2008-01-03
EP2353615B1 (de) 2014-11-19
US20080233119A2 (en) 2008-09-25

Similar Documents

Publication Publication Date Title
EP1667730A4 (de) Zusammensetzungen und verfahren zur behandlung von entzündlicher lungenerkrankung
HK1216080A1 (zh) 用於治療或預防草酸鹽相關疾病的組合物和方法
EP1737482A4 (de) Zusammensetzungen und verfahren zur behandlung von krankheiten
IL241756A0 (en) Preparations and methods for the treatment of diseases of safty tumors
IL172194A0 (en) Methods and compositions for treating amyloid-related diseases
EP1668024A4 (de) Oligonukleotidzusammensetzungen und verfahren zur behandlung von krankheiten einschliesslich entzündlicher leiden
AP2089A (en) Compositions and methods for combination antiviraltherapy
EP1692318A4 (de) Zusammensetzungen und verfahren zur diagnose und behandlung von lungenkrebs
IL184047A0 (en) Methods and compositions for treating amyloid-related diseases
IL180187A0 (en) Compositions and methods for treating inflammatory disorders
ZA200508427B (en) Methods for treating interleuking-6 related diseases
GB0411940D0 (en) Methods and compositions
EP1701725A4 (de) Verfahren und zusammensetzungen
ZA200508198B (en) Beta-carbolines useful for treating inflammatory disease
EP1545578A4 (de) Zusammensetzungen und verfahren zur behandlung von herz-kreislauf-erkrankungen
ZA200705297B (en) Methods and compositions for treating amyloid related diseases
IL183079A0 (en) Method and fluorinated compositions for treating amyloid-related diseases
TWI348479B (en) Impact-modified compositions and method
ZA200805419B (en) Compositions and methods for preventing or treating inflammatory bowel disease
AU2003212850A8 (en) Methods and compositions for treating cardiovascular disease
EP1765331A4 (de) Verfahren und zusammensetzungen zur behandlung von lungenerkrankungen
GB0303609D0 (en) Novel therapeutic method and compositions
EP1626711A4 (de) Zusammensetzungen und verfahren zur behandlung von krebs
ZA200610474B (en) Compositions and methods for treating inflammatory disorders
ZA200704093B (en) Methods and fluorinated compositions for treating amyloid-related diseases

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060317

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20080523

17Q First examination report despatched

Effective date: 20081021

RIN1 Information on inventor provided before grant (corrected)

Inventor name: FANG, LEI

Inventor name: PODACK, ECKHARD, R.

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20130410

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 618401

Country of ref document: AT

Kind code of ref document: T

Effective date: 20130715

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602004042551

Country of ref document: DE

Effective date: 20130822

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: FIAMMENGHI-FIAMMENGHI, CH

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130927

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130626

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2428321

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20131107

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130926

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130626

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130626

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130626

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130710

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130626

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130626

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130626

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130626

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E019115

Country of ref document: HU

26N No opposition filed

Effective date: 20140327

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602004042551

Country of ref document: DE

Effective date: 20140327

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CZ

Payment date: 20140804

Year of fee payment: 11

Ref country code: NL

Payment date: 20140809

Year of fee payment: 11

Ref country code: CH

Payment date: 20140812

Year of fee payment: 11

Ref country code: FI

Payment date: 20140812

Year of fee payment: 11

Ref country code: IE

Payment date: 20140812

Year of fee payment: 11

Ref country code: DE

Payment date: 20140813

Year of fee payment: 11

Ref country code: DK

Payment date: 20140812

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: HU

Payment date: 20140724

Year of fee payment: 11

Ref country code: SE

Payment date: 20140826

Year of fee payment: 11

Ref country code: AT

Payment date: 20140626

Year of fee payment: 11

Ref country code: FR

Payment date: 20140808

Year of fee payment: 11

Ref country code: GB

Payment date: 20140820

Year of fee payment: 11

Ref country code: ES

Payment date: 20140711

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20140808

Year of fee payment: 11

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130626

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130820

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602004042551

Country of ref document: DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

Effective date: 20150831

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 618401

Country of ref document: AT

Kind code of ref document: T

Effective date: 20150820

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20150820

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150831

Ref country code: CZ

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150820

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150820

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150831

REG Reference to a national code

Ref country code: NL

Ref legal event code: MM

Effective date: 20150901

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150820

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150821

Ref country code: HU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150821

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150820

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20160429

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150901

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130626

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150820

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150820

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160301

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150831

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150831

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20160927

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150821